Oramed Pharma (ORMP) Issues Shareholder Update

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials. In addition, management and the Board of Directors are examining the Company's existing pipeline and conducting a comprehensive review of strategic alternatives focused on enhancing shareholder value.

As part of this review process, Oramed will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. Oramed has not set a timetable for completion of this review process. There can be no assurance that this process will result in any such transaction and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction.

"Over the coming month, our clinical team will continue its deep dive into the unblinded Phase 3 data to assess the optimal way to move forward with our oral insulin assets as well as our platform technology," stated Chief Executive Officer, Nadav Kidron. "Concurrently, our management team and Board are also evaluating a broader range of strategic opportunities to enhance shareholder value."

You May Also Be Interested In

• Intel mulls partnership for Ohio chip fab, SK Hynix among candidates - report
• Magnolia Oil & Gas prices $500M senior notes due 2034
• NovaRed Amends Trojan-Condor Corridor Option Agreement